Storia in 9 fonti

Merck, Moderna Cancer Vaccine Breakthrough Puts 4 ETFs In Focus - Merck & Co (NYSE:MRK)

MRK, MRNA's cancer vaccine breakthrough could revive the mRNA trade, putting biotech and genomics ETFs back in focus.

Raccontata da

thehindubusinessline.com

arabnews.com

hindustantimes.com

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

benzinga.comStai leggendo12 h fa

Merck, Moderna Cancer Vaccine Breakthrough Puts 4 ETFs In Focus - Merck & Co (NYSE:MRK)

Moderna and Merck posted the first Phase 3 success for individualized mRNA cancer therapy (intismeran + Keytruda), marking mRNA's pivot from COVID vaccines to personalized oncology. This unlocks a multi-billion ecosystem—genomics, AI diagnostics, sequencing—potentially extending Keytruda's $31.7B revenue and reshaping precision-medicine investment thesis.

originale

Timeline cronologica

mercoledì 19 agosto 2026·biopharmadive.com
Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma
At an interim data check, investigators of a key trial found the individualized mRNA treatment kept disease from returning and stopped its spread, sparking a surge in Moderna…
mercoledì 19 agosto 2026·benzinga.com
Why Is BioNTech Stock Surging on Wednesday? - BioNTech (NASDAQ:BNTX)
BioNTech stock rises as Merck and Moderna report positive cancer vaccine data, highlighting its individualized mRNA cancer therapies.

Merck, Moderna Cancer Vaccine Breakthrough Puts 4 ETFs In Focus - Merck & Co (NYSE:MRK)

Confronto fonti

Merck, Moderna Cancer Vaccine Breakthrough Puts 4 ETFs In Focus - Merck & Co (NYSE:MRK)

Timeline cronologica

Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma

Why Is BioNTech Stock Surging on Wednesday? - BioNTech (NASDAQ:BNTX)

Moderna and Merck shares soar on mRNA cancer vaccine

Moderna's and Merck's personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in…

For Moderna, cancer vaccine results ease investor skepticism on its future as stock soars

Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma

Dow Jones Top Company Headlines at 3 PM ET: Moderna Shares More Than Double on Success of mRNA Cancer Vaccine…

Dow Jones Top Company Headlines at 1 PM ET: Moderna Shares Double on Success of mRNA Cancer Vaccine | Target ...

Moderna's and Merck's personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks…

For Moderna, cancer vaccine results ease investor skepticism on its future as stock soars

Dow Jones Top Company Headlines at 3 PM ET: Moderna Shares More Than Double on Success of mRNA Cancer Vaccine | OpenAI's ...

Moderna and Merck shares soar on mRNA cancer vaccine

Dow Jones Top Company Headlines at 5 PM ET: Moderna Shares More Than Double on Success of mRNA Cancer Vaccine | OpenAI's ...

Merck, Moderna Cancer Vaccine Breakthrough Puts 4 ETFs In Focus - Merck & Co (NYSE:MRK)

Health Care Up After Moderna Breakthrough — Health Care Roundup

Moderna, Merck breakthrough could usher in a wave of cancer vaccines

MRNA, BULL, BMNR, MSTR, MRK: 5 Trending Stocks Today - Moderna (NASDAQ:MRNA)

‘Breakthrough’ mRNA cancer drug curbs melanoma in large trial

mRNA’s second act: A bespoke cancer vaccine & what Merck-Moderna’s melanoma trial could mean for oncology

Elon Musk Backs mRNA As Moderna's Stock Soars on Cancer Vaccine Win - Moderna (NASDAQ:MRNA)

Healthcare Stocks After Hours: Moderna, Merck Cool Following Cancer Trial Gains - Pfizer (NYSE:PFE), Mode